What is Monod Bio?
Monod Bio operates at the intersection of synthetic biology and diagnostic hardware. The company specializes in the development of sophisticated biosensors capable of identifying complex molecular targets with high fidelity. By focusing on the detection of antibodies, toxins, and viral proteins, Monod Bio addresses a critical gap in current diagnostic capabilities, offering solutions that are essential for public health monitoring, therapeutic development, and environmental safety. Their Seattle-based operations benefit from a rich ecosystem of academic and research institutions, allowing the firm to maintain a competitive edge in the rapidly evolving biotech market.
How much funding has Monod Bio raised?
Monod Bio has raised a total of $31M across 2 funding rounds:
Angel/Seed
$6M
Angel/Seed
$25M
Angel/Seed (2021): $6M, investors not publicly disclosed
Angel/Seed (2022): $25M led by Global Health Investment Corporation, Cercano Management, Matrix Capital Advisors, Boom Capital Ventures, and Washington Research Foundation
Key Investors in Monod Bio
Washington Research Foundation
Washington Research Foundation supports research and scholarship in Washington state, with a focus on life sciences and enabling technologies through commercialization and grant-making.
Matrix Capital Advisors
Matrix Capital Advisors provides holistic wealth management and customized investment solutions tailored to each client's unique goals, needs and values.
Global Health Investment Corporation
A venture-focused organization dedicated to investing in technologies that address global health challenges and improve patient outcomes.
What's next for Monod Bio?
With the recent influx of capital, Monod Bio is expected to scale its operational capacity and expand its technical team. The strategic roadmap likely includes the refinement of its core biosensor architecture to support broader diagnostic applications and the initiation of pilot programs to validate the technology in real-world settings. As the company moves beyond its initial seed-stage milestones, the focus will shift toward establishing strategic partnerships with healthcare providers and pharmaceutical entities. This transition is critical for validating the commercial viability of their platform and ensuring that their molecular detection tools can be integrated into existing diagnostic workflows, ultimately driving long-term value for stakeholders and the broader scientific community.
See full Monod Bio company page
